PH12017500786B1 - Pharmaceutical composition comprising a beta blocker and an angiotensin converting enzyme inhibitor - Google Patents

Pharmaceutical composition comprising a beta blocker and an angiotensin converting enzyme inhibitor

Info

Publication number
PH12017500786B1
PH12017500786B1 PH12017500786A PH12017500786A PH12017500786B1 PH 12017500786 B1 PH12017500786 B1 PH 12017500786B1 PH 12017500786 A PH12017500786 A PH 12017500786A PH 12017500786 A PH12017500786 A PH 12017500786A PH 12017500786 B1 PH12017500786 B1 PH 12017500786B1
Authority
PH
Philippines
Prior art keywords
pharmaceutical composition
converting enzyme
enzyme inhibitor
angiotensin converting
beta blocker
Prior art date
Application number
PH12017500786A
Other versions
PH12017500786A1 (en
Inventor
Gilles Fonknechten
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52345359&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH12017500786(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of PH12017500786B1 publication Critical patent/PH12017500786B1/en
Publication of PH12017500786A1 publication Critical patent/PH12017500786A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

A fixed pharmaceutical composition comprising a beta-blocker, bisoprolol, and an angiotensin-converting enzyme inhibitor, perindopril, and use of said composition in the treatment and prevention of cardiovascular diseases and more specially arterial hypertension, stable coronary artery disease or chronic heart failure.
PH12017500786A 2014-11-05 2017-04-27 Pharmaceutical composition comprising a beta blocker and an angiotensin converting enzyme inhibitor PH12017500786A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1460654A FR3027803B1 (en) 2014-11-05 2014-11-05 PHARMACEUTICAL COMPOSITION COMPRISING A BETABLOQUANT AND A CONVERSION ENZYME INHIBITOR
PCT/FR2015/052975 WO2016071631A1 (en) 2014-11-05 2015-11-04 Pharmaceutical composition comprising bisoprolol and perindoril

Publications (2)

Publication Number Publication Date
PH12017500786B1 true PH12017500786B1 (en) 2017-10-02
PH12017500786A1 PH12017500786A1 (en) 2017-10-02

Family

ID=52345359

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12017500786A PH12017500786A1 (en) 2014-11-05 2017-04-27 Pharmaceutical composition comprising a beta blocker and an angiotensin converting enzyme inhibitor

Country Status (24)

Country Link
EP (1) EP3215130B1 (en)
CY (1) CY1123322T1 (en)
DK (1) DK3215130T3 (en)
EA (1) EA032808B1 (en)
ES (1) ES2811904T3 (en)
FR (1) FR3027803B1 (en)
GE (1) GEP20196989B (en)
HR (1) HRP20201518T1 (en)
HU (1) HUE051947T2 (en)
LT (1) LT3215130T (en)
MA (1) MA40915B1 (en)
MX (1) MX2017005848A (en)
MY (1) MY187357A (en)
PH (1) PH12017500786A1 (en)
PL (1) PL3215130T3 (en)
PT (1) PT3215130T (en)
RS (1) RS60657B1 (en)
RU (1) RU2702362C2 (en)
SG (2) SG10201903656RA (en)
SI (1) SI3215130T1 (en)
TN (1) TN2017000170A1 (en)
UA (1) UA122131C2 (en)
WO (1) WO2016071631A1 (en)
ZA (1) ZA201703078B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3234743A1 (en) 2021-10-20 2023-04-27 Les Laboratoires Servier Novel trimetazidine salts

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040137054A1 (en) 2002-05-03 2004-07-15 Alexandra Hager Stable pharmaceutical formulation for a combination of a statin and an ace-inhibitors
WO2007010501A2 (en) * 2005-07-22 2007-01-25 Ranbaxy Laboratories Limited A pharmaceutical composition comprising a combination of beta blocker and an ace inhibitor
HU230877B1 (en) * 2008-09-30 2018-11-29 EGIS Gyógyszergyár NyR Stable pharmaceutical combination
NZ596064A (en) * 2009-04-30 2014-03-28 Reddy’S Lab Ltd Dr Fixed dose drug combination formulations
EA201691986A1 (en) 2010-05-06 2017-03-31 СиЭйЭл ИНТЕРНЕШНЛ ЛИМИТЕД PHARMACEUTICAL COMPOSITION CONTAINING ASPIRIN AND BISOPROLOL

Also Published As

Publication number Publication date
MY187357A (en) 2021-09-22
ES2811904T3 (en) 2021-03-15
MX2017005848A (en) 2017-06-27
FR3027803B1 (en) 2018-02-09
MA40915B1 (en) 2020-08-31
LT3215130T (en) 2020-08-25
HRP20201518T1 (en) 2020-12-11
PT3215130T (en) 2020-08-26
HUE051947T2 (en) 2021-03-29
EA201790772A1 (en) 2017-09-29
RS60657B1 (en) 2020-09-30
RU2702362C2 (en) 2019-10-08
SG11201703550SA (en) 2017-06-29
SG10201903656RA (en) 2019-05-30
UA122131C2 (en) 2020-09-25
DK3215130T3 (en) 2020-09-21
EP3215130B1 (en) 2020-07-08
TN2017000170A1 (en) 2018-10-19
ZA201703078B (en) 2020-11-25
SI3215130T1 (en) 2020-11-30
PH12017500786A1 (en) 2017-10-02
FR3027803A1 (en) 2016-05-06
RU2017115341A3 (en) 2019-05-21
PL3215130T3 (en) 2020-11-16
WO2016071631A1 (en) 2016-05-12
GEP20196989B (en) 2019-07-10
EA032808B1 (en) 2019-07-31
RU2017115341A (en) 2018-11-05
EP3215130A1 (en) 2017-09-13
CY1123322T1 (en) 2021-12-31

Similar Documents

Publication Publication Date Title
MX2022007989A (en) Compositions and methods for treating pterygium.
MX2020009780A (en) Autotaxin inhibitor compounds.
EA201790765A1 (en) Derivatives of spirodiamine as inhibitors of aldosterone synthase
ES2352576T8 (en) INHIBITORS OF THE HUMAN IMMUNODEFICIENCY VIRUS REPLICATION.
NZ724002A (en) Liquid formulation comprising propylene glycol and an ace inhibitor
EA201500934A1 (en) CARDIO AND NEPHROPROTECTIVE ANTI-DIABETIC THERAPY
MX2022007436A (en) Autotaxin inhibitors and uses thereof.
PH12019501018A1 (en) Pharmaceutical composition, methods for treating and uses thereof
WO2015120372A3 (en) Compositions and methods to inhibit ezh2 for the treatment of cardiovascular diseases
EP3843620A4 (en) Self-calibrating, cuffless, and non-invasive blood pressure monitor
MY181835A (en) Humanized monoclonal antibody, inhibiting the enzymatic activity of vascular endothelial lipase
ZA202105111B (en) Pharmaceutical composition for the treatment of pulmonary arterial hypertension
MY193996A (en) Tripeptide compound, preparation method therefor, and application thereof
PH12017500786B1 (en) Pharmaceutical composition comprising a beta blocker and an angiotensin converting enzyme inhibitor
WO2015101670A3 (en) Inhibitors of 17beta-hydroxysteroid dehydrogenases type 1 and type 2
EP4038064C0 (en) N-substututed-6-oxo-1,6-dihydropyrimidine-2-yl derivatives as inhibitors of the human immunodeficiency virus replication
WO2016126572A3 (en) Glucosylceramide synthase inhibitors and therapeutic methods using the same
GB2549031A (en) Methods and drug therapies for patency of occluded blood vessels following angioplasty
WO2016144704A3 (en) Heterocyclic autotaxin inhibitor compounds
CL2020001578A1 (en) Improved compound for the treatment of heart failure.
NZ727147A (en) Combination therapy comprising olaratumab and doxorubicin
TN2018000344A1 (en) Pharmaceutical composition comprising a beta blocker, a converting enzyme inhibitor and an antihypertensive or an nsaid
EA202090028A1 (en) METHODS FOR REDUCING OR PREVENTING CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE II DIABETES
PH12020500472A1 (en) Autotaxin inhibitor compounds
MX2014015781A (en) Use of a1d-adrenergic antagonist, bmy-7378, for the treatment of prevention and reversal of the vascular hypertrophy in the arterial hypertension.